Summary
Boston Scientific Corporation (BSX) has announced a strategic divestiture alongside its ongoing acquisition of BTG plc. As part of the BTG acquisition process, Boston Scientific has entered into an agreement to sell its existing drug-eluting and bland embolic microsphere business to Varian Medical Systems, Inc. This business includes key products such as ONCOZENETM, EMBOZENETM, and EMBOZONE TANDEMTM. The sale is contingent upon the successful completion of the BTG acquisition and is anticipated to close immediately thereafter. This move suggests a strategic realignment by Boston Scientific, potentially focusing its resources on core areas post-acquisition. Investors should monitor the progress of the BTG acquisition and the financial implications of this divestiture.
Key Highlights
- 1Boston Scientific is selling its drug-eluting and bland embolic microsphere business to Varian Medical Systems, Inc.
- 2The divested business includes product lines like ONCOZENETM, EMBOZENETM, and EMBOZONE TANDEMTM.
- 3The sale is conditional upon the completion of the acquisition of BTG plc.
- 4The transaction is expected to close immediately after the BTG acquisition is finalized.
- 5This divestiture is a consequence of Boston Scientific's ongoing acquisition of BTG plc.